SHANGHAI, NEW JERSEY — May 16th, 2024 — Oricell Therapeutics, a clinical-stage biotechnology company at the forefront of developing innovative therapies for life-threatening diseases, is pleased to announce its participation in the upcoming ASCO 2024 Annual Meeting（31th May-4th June). The Company will deliver an oral presentation and two poster presentations, highlighting updated clinical data from POLARIS study that evaluates OriCAR-017, a GPRC5D targeted CAR-T program, as well as showcasing other novel therapeutic approaches.
Abstracts for the oral and poster presentations can be found below:
| Abstract Number | Title | Information |
| Oral presentation | OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS). | Session Type: Rapid Oral Abstract Session Session Title: Hematologic Malignancies—Plasma Cell Dyscrasia |
About OriCAR-017
OriCAR-017, a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D, is a groundbreaking innovation in the treatment of relapsed/refractory multiple myeloma(RRMM). Leveraging Oricell Therapeutics' cutting-edge proprietary technology platforms, OriCAR-017 exhibits clearly differentiated binding avidity, persistence, anti-tumor efficacy and safety performance. OriCAR-017 received IND approval from FDA in Jan 2024 after its approval by NMPA in 2023 and impressive clinical results from the POLARIS study.
The latest data showed that all ten patients with R/R MM responded to the therapy per IMWG criteria, achieving a 100% overall response rate (ORR), 80% stringent complete response. 100% minimal residual disease (MRD) negative rate was detected at day 28 and further confirmed at month 3. The therapy was well-tolerated, with no Immune effector cell-associated neurotoxicity syndrome (ICANS), no cerebellar disorder, no delayed infections, and only Grade 1/Grade 2 CRS that resolved rapidly.
It's worth noting that the study included patients with complex and advanced disease characteristics. Among the ten R/R MM patients, 40% had extramedullary disease (EMD), 50% had undergone one or more BCMA-directed CAR-T treatments, 70% had high-risk cytogenetics, 70% were classified as ECOG 2 score status, and 80% were at International Staging System (ISS) stages II & III. OriCAR-017 demonstrates its potential as a safe and effective treatment option for patients, marking a substantial progress in the fight against RRMM and offering hope to those facing demanding health conditions.
Currently, Oricell has assembled a skilled team in both the US and China, collaboratively accelerating clinical development globally.
沪公网安备 31011502019994号